Herein we report evidence that administration of purified recombinant human KLK-1 (DM199) elicits improvements in fasting blood glucose levels, and improves whole-body glucose disposal in preclinical animal models of T2D. Here, KLK1 is linked to type 2 diabetes mellitus.